BWH 01
Alternative Names: BWH-01Latest Information Update: 08 Oct 2025
At a glance
- Originator Argo Biopharma
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cardiovascular disorders
Most Recent Events
- 28 Aug 2025 Early research in Cardiovascular disorders in China (Parenteral) before August 2025 (Argo Biopharma pipeline, August 2025)